In particular, we found that carnitine and short-chain acylcarnitines were reduced in concentration in HB and that the carnitine metabolic pathway was dysregulated in the tumours (CPT1a, CPT2 and SLC25A20). This evidence concerns the gene SLC25A20 and neoplasm.